• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心脏病专家眼中的COVID-19:基础病毒学、流行病学、心脏表现及潜在治疗策略

COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies.

作者信息

Atri Deepak, Siddiqi Hasan K, Lang Joshua P, Nauffal Victor, Morrow David A, Bohula Erin A

机构信息

Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

出版信息

JACC Basic Transl Sci. 2020 Apr 10;5(5):518-536. doi: 10.1016/j.jacbts.2020.04.002. eCollection 2020 May.

DOI:10.1016/j.jacbts.2020.04.002
PMID:32292848
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7151394/
Abstract

Coronavirus disease-2019 (COVID-19), a contagious disease caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has reached pandemic status. As it spreads across the world, it has overwhelmed health care systems, strangled the global economy, and led to a devastating loss of life. Widespread efforts from regulators, clinicians, and scientists are driving a rapid expansion of knowledge of the SARS-CoV-2 virus and COVID-19. The authors review the most current data, with a focus on the basic understanding of the mechanism(s) of disease and translation to the clinical syndrome and potential therapeutics. The authors discuss the basic virology, epidemiology, clinical manifestation, multiorgan consequences, and outcomes. With a focus on cardiovascular complications, they propose several mechanisms of injury. The virology and potential mechanism of injury form the basis for a discussion of potential disease-modifying therapies.

摘要

2019冠状病毒病(COVID-19)是一种由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的传染病,已达到大流行状态。随着它在全球范围内传播,它使医疗系统不堪重负,扼杀了全球经济,并导致了毁灭性的生命损失。监管机构、临床医生和科学家的广泛努力正在推动对SARS-CoV-2病毒和COVID-19的认识迅速扩展。作者回顾了最新数据,重点是对疾病机制的基本理解以及向临床综合征和潜在治疗方法的转化。作者讨论了基本病毒学、流行病学、临床表现、多器官后果和结局。他们重点关注心血管并发症,提出了几种损伤机制。病毒学和潜在损伤机制构成了对潜在疾病改善疗法讨论的基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18b9/7251187/7a17ade60369/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18b9/7251187/7a17ade60369/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18b9/7251187/b7194ad63e94/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18b9/7251187/7a17ade60369/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18b9/7251187/7a17ade60369/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18b9/7251187/b7194ad63e94/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18b9/7251187/7a17ade60369/gr2.jpg

相似文献

1
COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies.心脏病专家眼中的COVID-19:基础病毒学、流行病学、心脏表现及潜在治疗策略
JACC Basic Transl Sci. 2020 Apr 10;5(5):518-536. doi: 10.1016/j.jacbts.2020.04.002. eCollection 2020 May.
2
Coronavirus disease 2019 and cardiovascular system: A narrative review.2019年冠状病毒病与心血管系统:一篇综述
Int J Cardiol Heart Vasc. 2020 Jun 3;29:100557. doi: 10.1016/j.ijcha.2020.100557. eCollection 2020 Aug.
3
SARS-CoV-2 infection and smoking: What is the association? A brief review.新型冠状病毒2019感染与吸烟:有何关联?简要综述。
Comput Struct Biotechnol J. 2021;19:1654-1660. doi: 10.1016/j.csbj.2021.03.023. Epub 2021 Mar 23.
4
Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).血管紧张素转化酶 2(ACE2)、严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)与 2019 冠状病毒病(COVID-19)的病理生理学。
J Pathol. 2020 Jul;251(3):228-248. doi: 10.1002/path.5471. Epub 2020 Jun 10.
5
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
6
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.TMPRSS2 抑制剂那法莫司他可降低 COVID-19 小鼠模型中的 SARS-CoV-2 肺部感染。
mBio. 2021 Aug 31;12(4):e0097021. doi: 10.1128/mBio.00970-21. Epub 2021 Aug 3.
7
Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review.SARS-CoV-2 对心血管系统的影响:血管紧张素转换酶 2(ACE2)作为病毒受体和体内平衡调节剂的双重作用——综述。
Int J Mol Sci. 2021 Apr 26;22(9):4526. doi: 10.3390/ijms22094526.
8
Human and novel coronavirus infections in children: a review.儿童人感染和新型冠状病毒感染:综述。
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
9
Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart.单细胞分析 SARS-CoV-2 受体 ACE2 和刺突蛋白在人心脏中对蛋白酶的预激活表达。
Cardiovasc Res. 2020 Aug 1;116(10):1733-1741. doi: 10.1093/cvr/cvaa191.
10
COVID-19 and Kidney Disease: Update on Epidemiology, Clinical Manifestations, Pathophysiology and Management.2019冠状病毒病与肾脏疾病:流行病学、临床表现、病理生理学及管理的最新进展
J Coll Physicians Surg Pak. 2020 Jun;30(6):19-25. doi: 10.29271/jcpsp.2020.Supp1.S19.

引用本文的文献

1
Relation between COVID-19 vaccination and myocardial infarction - Casual or coincidental?2019冠状病毒病疫苗接种与心肌梗死之间的关系——是因果关系还是巧合?
IHJ Cardiovasc Case Rep. 2021 May-Aug;5(2):71-74. doi: 10.1016/j.ihjccr.2021.05.003. Epub 2021 Jun 7.
2
Peculiarities of in-Stent Thrombosis and Restenosis in Coronary Arteries Post-COVID-19: A Systematic Review of Clinical Cases and Case Series.新冠病毒感染后冠状动脉内支架内血栓形成和再狭窄的特点:临床病例和病例系列的系统评价
Open Access Emerg Med. 2025 Jan 22;17:15-30. doi: 10.2147/OAEM.S470523. eCollection 2025.
3
COVID-19 and Cardiac Arrhythmias: Lesson Learned and Dilemmas.

本文引用的文献

1
First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients.首个使用丙肝病毒蛋白酶抑制剂达诺普韦治疗新冠肺炎患者的临床研究。
Medicine (Baltimore). 2020 Nov 25;99(48):e23357. doi: 10.1097/MD.0000000000023357.
2
COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal.新冠病毒疾病在自然状态和免疫抑制状态下:一项临床治疗分期建议。
J Heart Lung Transplant. 2020 May;39(5):405-407. doi: 10.1016/j.healun.2020.03.012. Epub 2020 Mar 20.
3
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
新冠病毒肺炎与心律失常:经验教训与困境
J Clin Med. 2024 Nov 29;13(23):7259. doi: 10.3390/jcm13237259.
4
Cardiac Damage After SARS-CoV2 Infection.新型冠状病毒2感染后的心脏损伤。
Cureus. 2024 May 19;16(5):e60641. doi: 10.7759/cureus.60641. eCollection 2024 May.
5
The Emerging Field of Cardioimmunology: Past, Present and Foreseeable Future.心血管免疫学期望:过去、现在和可预见的未来
Circ Res. 2024 Jun 7;134(12):1663-1680. doi: 10.1161/CIRCRESAHA.123.323656. Epub 2024 Jun 6.
6
Cardiac SARS-CoV-2 Infection, Involvement of Cytokines in Postmortem Immunohistochemical Study.心脏SARS-CoV-2感染,细胞因子在尸检免疫组织化学研究中的作用
Diagnostics (Basel). 2024 Apr 9;14(8):787. doi: 10.3390/diagnostics14080787.
7
Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center Study.住院的长期新冠病毒感染患者继发性硬化性胆管炎的发病率:一项回顾性单中心研究
Diagnostics (Basel). 2024 Mar 30;14(7):745. doi: 10.3390/diagnostics14070745.
8
Role of epinephrine in attenuating cytokine storm, decreasing ferritin, and inhibiting ferroptosis in SARS-CoV-2.肾上腺素在减轻细胞因子风暴、降低铁蛋白以及抑制新型冠状病毒中的铁死亡方面的作用。
Egypt Heart J. 2024 Feb 20;76(1):22. doi: 10.1186/s43044-024-00455-9.
9
Cardiac arrhythmia in COVID-19 patients.COVID-19 患者的心律失常。
Ann Noninvasive Electrocardiol. 2024 Mar;29(2):e13105. doi: 10.1111/anec.13105.
10
Comparison of violence and aggressions suffered by health personnel during the COVID-19 pandemic in Argentina and the rest of Latin America.阿根廷与拉丁美洲其他地区在 COVID-19 大流行期间卫生人员所遭受的暴力和侵犯行为比较。
Rev Peru Med Exp Salud Publica. 2023 Apr-Jun;40(2):179-188. doi: 10.17843/rpmesp.2023.402.12646.
一种 SARS-CoV-2 蛋白相互作用图谱揭示了药物再利用的靶标。
Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9. Epub 2020 Apr 30.
4
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
5
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.使用临床级别的可溶性人血管紧张素转化酶 2 抑制工程化人类组织中的 SARS-CoV-2 感染。
Cell. 2020 May 14;181(4):905-913.e7. doi: 10.1016/j.cell.2020.04.004. Epub 2020 Apr 24.
6
ST-Segment Elevation in Patients with Covid-19 - A Case Series.新型冠状病毒肺炎患者的ST段抬高——病例系列
N Engl J Med. 2020 Jun 18;382(25):2478-2480. doi: 10.1056/NEJMc2009020. Epub 2020 Apr 17.
7
Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020.2020 年 1 月 23 日至 3 月 16 日新加坡出现的 SARS-CoV-2 病前传播。
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):411-415. doi: 10.15585/mmwr.mm6914e1.
8
Kidney disease is associated with in-hospital death of patients with COVID-19.肾病与 COVID-19 患者住院期间的死亡相关。
Kidney Int. 2020 May;97(5):829-838. doi: 10.1016/j.kint.2020.03.005. Epub 2020 Mar 20.
9
Estimates of the severity of coronavirus disease 2019: a model-based analysis.新型冠状病毒疾病 2019 严重程度的估计:基于模型的分析。
Lancet Infect Dis. 2020 Jun;20(6):669-677. doi: 10.1016/S1473-3099(20)30243-7. Epub 2020 Mar 30.
10
Likelihood of survival of coronavirus disease 2019.2019冠状病毒病的生存可能性。
Lancet Infect Dis. 2020 Jun;20(6):630-631. doi: 10.1016/S1473-3099(20)30257-7. Epub 2020 Mar 30.